Cargando…

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma

Aberrant expression of microRNAs (miRNAs) has been associated to the pathogenesis of multiple myeloma (MM). While miR-155 is considered a therapeutic target in several malignancies, its role in MM is still unclear. The analysis of miR-155 expression indicates its down-regulation in MM patient-derive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amodio, Nicola, Gallo Cantafio, Maria Eugenia, Botta, Cirino, Agosti, Valter, Federico, Cinzia, Caracciolo, Daniele, Ronchetti, Domenica, Rossi, Marco, Driessen, Christoph, Neri, Antonino, Tagliaferri, Pierosandro, Tassone, Pierfrancesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406286/ https://www.ncbi.nlm.nih.gov/pubmed/30781685 http://dx.doi.org/10.3390/cancers11020236

Ejemplares similares

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
por: Stamato, Maria Angelica, et al.
Publicado: (2017)

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
por: Amodio, Nicola, et al.
Publicado: (2015)

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities
por: Botta, Cirino, et al.
Publicado: (2014)

miR-22 suppresses DNA ligase III addiction in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2018)

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
por: Pitari, Maria Rita, et al.
Publicado: (2015)

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
por: Amodio, Nicola, et al.
Publicado: (2018)

Mouse models of multiple myeloma: technologic platforms and perspectives
por: Rossi, Marco, et al.
Publicado: (2018)

LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?
por: Taiana, Elisa, et al.
Publicado: (2020)

Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer
por: Correale, Pierpaolo, et al.
Publicado: (2012)

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2016)

Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells
por: Todoerti, Katia, et al.
Publicado: (2021)

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
por: Staropoli, Nicoletta, et al.
Publicado: (2013)

Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
por: Amodio, Nicola, et al.
Publicado: (2018)

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
por: Cucè, Maria, et al.
Publicado: (2019)

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias
por: Morelli, Eugenio, et al.
Publicado: (2020)

In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells
por: Di Martino, Maria Teresa, et al.
Publicado: (2014)

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
por: Di Martino, Maria Teresa, et al.
Publicado: (2013)

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity
por: Raimondi, Lavinia, et al.
Publicado: (2014)

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats
por: Di Martino, Maria Teresa, et al.
Publicado: (2020)

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes
por: Agapito, Giuseppe, et al.
Publicado: (2016)

Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma
por: Di Martino, Maria Teresa, et al.
Publicado: (2015)

MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment
por: Raimondi, Lavinia, et al.
Publicado: (2016)

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice
por: Arbitrio, Mariamena, et al.
Publicado: (2020)

Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma
por: Juli, Giada, et al.
Publicado: (2019)

Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell Growths
por: Limongi, Tania, et al.
Publicado: (2020)

The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives
por: Caracciolo, Daniele, et al.
Publicado: (2023)

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2020)

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2021)

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells
por: Botta, C, et al.
Publicado: (2018)

MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers
por: Settino, Marzia, et al.
Publicado: (2020)

mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials
por: Rotundo, Maria Saveria, et al.
Publicado: (2016)

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221
por: Di Martino, Maria Teresa, et al.
Publicado: (2019)

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation
por: Staropoli, Nicoletta, et al.
Publicado: (2016)

miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy
por: Di Martino, Maria Teresa, et al.
Publicado: (2021)

Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes
por: Scionti, Francesca, et al.
Publicado: (2022)

Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2020)

Analysis of miRNA, mRNA, and TF interactions through network-based methods
por: Guzzi, Pietro H, et al.
Publicado: (2015)

GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2023)

Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs
por: D’Aquila, Patrizia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fa4vpl8uu2rq9cf56n1ihcqhbh